Wan Sakeenah Wan Nazri1, Noor Atiqah Fakharuzi1*, Kamal Shaik Fakiruddin1, Yuslina Mat Yusoff2, Sujatha Suthandiram2, Adiratna Mat Ripen2, Lim Moon Nian1
1. Good Manufacturing Practice (GMP) Laboratory, Biomedical Research Core Facility (BioRCF), Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia (MOH), Setia Alam, 40170 Shah Alam, Selangor, Malaysia
2. Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia (MOH), Setia Alam, 40170 Shah Alam, Selangor, Malaysia
*Corresponding author: Noor Atiqah Fakharuzi.
ABSTRACT
INTRODUCTION: Cell and gene therapy product (CGTP) manufacturing is highly sensitive to environmental contamination, requiring robust cleanroom control and regulatory compliance. Environmental Monitoring (EM) programs are essential for detecting viable and non-viable contaminants, but to our knowledge, limited reports exist on the implementation, maintenance, and risk-driven refinement of EM programs tailored for CGT facilities.
OBJECTIVE(S): This study aimed to evaluate the effectiveness of a three-year EM program in a GMP manufacturing facility. Using Failure Mode and Effects Analysis (FMEA), we identified critical risks, assessed contamination sources, and prioritized mitigation strategies particularly involving the HVAC system in the aseptic processing area.
MATERIALS & METHODS: EM was conducted in Grade B, C, and D cleanrooms. Microbiological monitoring included viable particle detection using passive methods (settle plates, contact plates, and glove prints). Physical monitoring included non-viable particle counts, differential pressure, temperature, and relative humidity. HVAC systems underwent Cleanroom Performance Testing (CPT) as per Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidelines, which include parameters such as terminal HEPA/ULPA filter leak test, airflow volume and total air change rate test, room recovery test, airflow visualisation test. FMEA was used to identify failure modes and assess their potential impact on product quality.
RESULTS: A total of six failure modes were identified, and a Risk Priority Number (RPN) was assigned to each mode to evaluate their relative risk. The highest risks were associated with improper gowning and biosafety cabinet operations. Indicators such as pressure differentials, glove print contamination, and non-viable particle excursions were selected for ongoing risk monitoring. HVAC performance remained compliant with PIC/S standards, and environmental data supported a controlled and stable manufacturing environment.
CONCLUSION: Implementing FMEA to environmental monitoring enhances the control of contamination risks in CGTP manufacturing. This integrated strategy supports GMP compliance and strengthens facility readiness for advanced therapy production.
KEYWORDS: GMP, MSC, FMEA, Risk Assessment, Environmental Monitoring


